Article: PDF OnlyFibrinolysis and fibrinogenolysis in patients with thrombotic diseaseTakahashi, H.; Wada, K.; Hanano, M.; Niwano, H.; Takizawa, S.; Yazawa, Y.; Shibata, A.Author Information H. Takahashi, K. Wada, M. Hanano, H. Niwano and A. Shibata are with the First Department of Internal Medicine, Niigata University School of Medicine, 1–754 Asahimachi, Niigata 951, Japan. S. Takizawa and Y, Yazawa are with the Division of Internal Medicine, Kobari Hospital, Niigata 950− 21, Japan. Blood Coagulation & Fibrinolysis: April 1992 - Volume 3 - Issue 2 - p 193-202 Buy Abstract In order to assess the fibrinolytic state in thrombotic disease, plasma levels of fibrin degradation products (FbDP) and fibrinogen degradation products (FgDP) were measured in 126 patients with a variety of thrombotic diseases. Mean plasma concentrations of both FbDP and FgDP were significantly elevated in patients with thrombotic disease as compared with healthy subjects. Plasma concentrations of FgDP were positively correlated with FbDP (r = 0.667, P < 0.001). When analysed according to the disease categories, the magnitude of elevations of FbDP and FgDP was most prominent in venous thrombotic disease such as deep vein thrombosis and pulmonary embolism. These findings indicate that fibrinolysis is accelerated in patients with thrombotic disease and that fibrinolysis is frequently accompanied by some fibrinogenolysis in these patients. © Lippincott-Raven Publishers.